Results from the HOPE-3 randomized trial reinforce and expand the evidence base supporting current clinical practice guidelines that recommend initiation of statin therapy in individuals at intermediate risk of atherosclerotic events. Furthermore, the results support the initiation of antihypertensive medication for patients with blood pressure above threshold values.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yusuf, S. et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1600176 (2016).
Lonn, E. M. et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1600175 (2016).
Yusuf, S. et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1600177 (2016).
Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation 129 (Suppl. 2), S1–S45 (2013).
Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).
Downs, J. R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279, 1615–1622 (1998).
Nakamura, H. et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet 368, 1155–1163 (2006).
The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 373, 2103–2116 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Wilkins, J., Lloyd-Jones, D. HOPE-3 trial — targeting BP and LDL-C in at-risk patients. Nat Rev Cardiol 13, 315–316 (2016). https://doi.org/10.1038/nrcardio.2016.74
Published:
Issue date:
DOI: https://doi.org/10.1038/nrcardio.2016.74
